Generic medicines are not substandard medicines [7] (multiple letters)

Lancet

Volumn 359, Issue 9314, 2002, Pages 1351-1352

  Ford, Nathan ^a   'T Hoen, Ellen ^a   Adelman, Carol ^b   Norris, Jeremiah ^b  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b HUDSON INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIINFECTIVE AGENT; GENERIC DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DEVELOPING COUNTRY; DRUG COST; DRUG EFFICACY; DRUG QUALITY; DRUG SAFETY; FUNGAL MENINGITIS; HUMAN; LEISHMANIASIS; LETTER; PRIORITY JOURNAL; TRACHOMA; WORLD HEALTH ORGANIZATION;

EID: 0037070731     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(02)08303-4     Document Type: Letter

References (5)

1. RB Taylor O Shakoor RH Behrens Pharmacopoeial quality of drugs supplied by Nigerian pharmacies Lancet 357 2001 1933 1936
2. A Li Wan Po Too much, too little, or none at all: dealing with substandard and fake drugs Lancet 357 2001 1904
3. Implementation of WHO's revised drug strategy: safety and efficacy of pharmaceutical products—forty-fifth World Health Assembly 1992, March 18 WHO Geneva
4. RH Rubin A comparative analysis of some drugs on the EDL. A discussion paper on the issues raised by a WHO resolution vis-à-vis US trade interests Oct 3, 1996 Harvard Medical International Boston, MA
5. A Attaran L Gillespie-White Do patents for antiretroviral drugs constrain access to AIDS treatment in Africa? JAMA 286 2001 1886 1892